NR4A1 and neoplasm: Although assessing the standard variables (e.g., age, menopausal status, tumor size, lymph node status, histological grade, lymph vascular invasion, hormone receptor (HR), HER2, and Ki67 labeling index) can be highly informative for many patients, ~15% of women with stage I–III hormone receptor-positive (HR+) disease will go through metastatic events [4].